Cargando…
Evolving Ablative Therapies for Hepatic Malignancy
The liver is a common site for both primary and secondary malignancy. Hepatic resection and transplantation are the two treatment modalities that have been shown to achieve complete cure, but only 10 to 20% of patients are candidates for these treatments. For the remaining patients, tumor ablation h...
Autores principales: | Singla, Smit, Hochwald, Steven N., Kuvshinoff, Boris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022034/ https://www.ncbi.nlm.nih.gov/pubmed/24877069 http://dx.doi.org/10.1155/2014/230174 |
Ejemplares similares
-
Ablative Therapies for Colorectal Polyps and Malignancy
por: Oxenberg, Jacqueline, et al.
Publicado: (2014) -
Ablative Therapy for Esophageal Dysplasia and Early Malignancy: Focus on RFA
por: Tuttle, Rebecca, et al.
Publicado: (2014) -
Ablative Therapy in Non-HCC Liver Malignancy
por: Robinson, Tyler P., et al.
Publicado: (2023) -
Giant Hepatic Hemangioma With Kasabach–Merritt
Syndrome: Is the Appropriate Treatment
Enucleation or Liver Transplantation?
por: Hochwald, Steven N., et al.
Publicado: (2000) -
Evolving Role of Catheter Ablation for Atrial Fibrillation: Early and Effective Rhythm Control
por: Chen, Shaojie, et al.
Publicado: (2022)